CO SB121

Department of Health Care Policy and Financing must seek federal authorization by January 1, 2026, to reimburse acute care hospitals and ambulatory surgery facilities for vagus nerve stimulation therapy for Medicaid members with drug-resistant epilepsy

Initial reimbursement rate set at 60% of the cost for acquiring the vagus nerve stimulator device

Reimbursement rate increases to 75% of device acquisition cost beginning January 1, 2029

Device reimbursement is separate from and does not replace reimbursement for the surgical implantation procedure

State department must adopt rules necessary to implement the new reimbursement requirements